BioFocus announced today that it has established an innovative and unique model for the sale of its SoftFocus compound libraries. Going forward, BioFocus will provide a limited number of clients with SoftFocus libraries on a subscription basis only. These libraries are designed to target protein families of particular interest to the subscribers. This shared exclusivity model will allow clients access to high value, novel compounds with limited competition on derived intellectual property.

“Our SoftFocus libraries have enjoyed a decade of success”, said Richard Gordon, Senior Director Sales and Marketing, BioFocus. “The introduction of this shared exclusivity model is a consequence of the success that the libraries have yielded for our clients. Our clients want a better position on IP generated from screening the libraries and we have adapted our model to accommodate their needs. This is a true testament to the value that our clients see in the SoftFocus brand.”

BioFocus will continue to provide support to customers of the existing SoftFocus non-exclusive libraries through the open access chemical structure search engine, eMolecules, and BioFocus’ improved resynthesis, scaffold and protocol program. The eMolecules platform allows users to search structural information and order pre-2011 SoftFocus compounds online. More information at: www.biofocus.emolecules.com.

About BioFocus

BioFocus aims to expand its partners’ drug pipelines by accelerating the gene-to-drug candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services. As a service division of Galapagos, BioFocus has over 250 employees in four countries worldwide.